▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool Healthcare Analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, and marijuana. Prior to The Motley Fool, Speights was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

DNA Double Helix

May 3, 2018 by Keith Speights

For Pacific Biosciences of California, a First Quarter Hurt by Shipment Delays

The gene-sequencing company received plenty of orders for its Sequel systems in the first quarter, but customers weren't ready for most of them.

Cerner medical staff in hospital

May 3, 2018 by Keith Speights

Cerner Corporation Cuts 2018 Outlook on Weak First Quarter

The delay of a major contract contributed to the healthcare technology leader missing its first-quarter revenue forecast.

Masimo systems in hospital

May 3, 2018 by Keith Speights

Masimo Corporation's Strong First Quarter Spurs an Upgrade to Its 2018 Outlook

The maker of non-invasive monitoring technologies reported a record quarter, thanks to solid sales growth of its SET pulse oximetry products.

Worry and eraser

May 3, 2018 by Keith Speights

5 Reasons You Shouldn't Worry About Gilead Sciences' Ugly Q1 Results

There are several silver linings in the dark cloud hanging over the big biotech.

Globus Medical ExcelciusGPS

May 3, 2018 by Keith Speights

Globus Medical Inc. Boosts 2018 Outlook After a Strong First Quarter

The new ExcelsiusGPS robotics and navigation system generates big sales growth for the medical-device company in the first quarter.

cvs-health-female-pharmacist-with-patient-cvs-pharmacy

May 2, 2018 by Keith Speights

Retail Steps Up in CVS Health Corporation's First Quarter

The pharmacy services giant usually sees faster growth from its PBM instead of its retail segment -- but not this time around.

Scientists with DNA

Jun 4, 2018 by Keith Speights

What Diseases Could Gene Editing Cure?

There are over 10,000 genetic diseases. Here are the ones that could be cured by gene editing in the not-too-distant future.

Woman making decision

May 2, 2018 by Keith Speights

Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)

These two big pharma stocks have a lot in common. But only one is the better choice right now.

Chart going down

May 2, 2018 by Keith Speights

Gilead Sciences' First-Quarter Twist: Weak HIV Sales

Continued HCV sales declines for the big biotech were expected, but not anemic growth for its HIV franchise.

DNA image over hand

Jun 4, 2018 by Keith Speights

Top Gene-Editing Stocks for Long-Term Investors

These stocks could be poised to profit from one of the biggest advancements in medical history.

Businessman with magnifying glass

May 1, 2018 by Keith Speights

3 Numbers That Should Grab Your Attention in Merck's Q1 Earnings

Hint: Earnings isn't one of them.

Pfizer scientists from Pfizer website

May 1, 2018 by Keith Speights

Pfizer Q1 Earnings: What You Need to Know

Why the big drugmaker reported a revenue miss but an earnings beat in the first quarter.

Ben Franklin peaking through pills

May 1, 2018 by Keith Speights

4 Things to Expect in CVS Health's Q1 Earnings Results

Some good news should be on the way in Q1 for the pharmacy giant.

Scientists side by side with test tubes

May 1, 2018 by Keith Speights

Better Buy: Biogen Inc. vs. Gilead Sciences Inc.

Which big biotech wins in a head-to-head matchup?

Couple in their 60s looking at PC

Apr 30, 2018 by Keith Speights

In Your 60s? 3 Stocks You Should Consider Buying

These stocks have the right stuff for investors approaching retirement or who are already there.

3 scientists in lab

Apr 30, 2018 by Keith Speights

Allergan's Q1 Earnings: What You Need to Know

The beaten-down drugmaker beats expectations in Q1, but still faces challenges.

Scientist Zika Virus

Apr 30, 2018 by Keith Speights

Is Inovio Pharmaceuticals, Inc. (INO) a Buy?

Weighing the arguments for and against the clinical-stage biotech.

Businessman holding dart with hands over his eyes

Apr 29, 2018 by Keith Speights

Are Canadian Marijuana Stock CEOs Absolutely, Positively Crazy?

CEOs of Canadian marijuana growers look like they're trying to defy the laws of supply and demand -- at least at first glance.

Financial report

Apr 29, 2018 by Keith Speights

What to Expect with Pfizer's Q1 Results

And what not to expect, too.

Face of scientist in lab with beaker

Apr 29, 2018 by Keith Speights

What to Expect With Gilead Sciences Inc.'s Q1 Earnings Results

Plus a few things that you shouldn't expect from the big biotech.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services